Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

R. J. Motzer*, N. M. Tannir, D. F. McDermott, O. Arén Frontera, B. Melichar, T. K. Choueiri, E. R. Plimack, P. Barthélémy, C. Porta, S. George, T. Powles, F. Donskov, V. Neiman, C. K. Kollmannsberger, P. Salman, H. Gurney, R. Hawkins, A. Ravaud, M. O. Grimm, S. BracardaC. H. Barrios, Y. Tomita, D. Castellano, B. I. Rini, A. C. Chen, S. Mekan, M. B. McHenry, M. Wind-Rotolo, J. Doan, P. Sharma, H. J. Hammers, B. Escudier, CheckMate 214 Investigators

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3088 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences